RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney FibrosisPRNewsWire • 09/07/21
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare ConferencesPRNewsWire • 09/02/21
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/26/21
RedHill Biopharma reports second quarter 2021 results, showing record quarterly revenuesProactive Investors • 08/26/21
RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta VariantBenzinga • 08/26/21
RedHill Biopharma demonstrates strong inhibition by opaganib of the coronavirus (COVID-19) Delta variantProactive Investors • 08/26/21
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 08/26/21
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant InhibitionAccesswire • 08/26/21
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta VariantPRNewsWire • 08/26/21
RedHill Biopharma says USPTO has issued it with two new patents for opaganib for Ebola Virus and RHB-104 for Crohn'sProactive Investors • 08/23/21
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn'sPRNewsWire • 08/23/21
RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021PRNewsWire • 08/19/21
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with ApotexPRNewsWire • 07/22/21